The U.S. Food and Drug Administration designated psilocybin as a “breakthrough therapy” for treatment-resistant depression in 2018 and for major depressive disorder in 2019.
AI tools are helping researchers discover new drugs more quickly
During the last nine years, the cumulative amount of AI investments across the pharma and biotech sectors has increased by almost thirtyfold, to $24.6 billion as of last December.Read More
Lilly stock skyrockets, raising profile of city’s life sciences sector
The pharmaceutical company has launched 20 drugs in the past decade to treat diseases from arthritis and psoriasis to diabetes and cancer. In recent months, Lilly has overtaken every competitor to become the most valuable drugmaker in the world.Read More
Former top IU med school researcher says why he left
The IU School of Medicine scored a major coup five years ago when it recruited one of the nation’s top experts in the fast-growing field of regenerative medicine. But the University of Pittsburgh recruited him away this spring.Read More
Riley Children’s Foundation lands $10M gift from Walther Cancer Foundation
Walther will provide a one-for-one match for donors who establish endowed children’s cancer research funds at Riley Children’s Foundation, a move that could result in at least $20 million for research of new treatments of children’s cancers.Read More
The research published by the IU Richard M. Fairbanks School of Public Health found that one in five Indiana residents with mental illness do not receive the treatment they need.
A number of studies have found that people receiving vaccinations for flu and several other infectious diseases appear less likely than the unvaccinated to develop dementia, although scientists aren’t sure why.
People who endured even mild cases of COVID-19 are at heightened risk two years later for lung problems, fatigue, diabetes and certain other health problems typical of long COVID, according to a new study that casts fresh light on the virus’s true toll.
The study did not say the medications cause dementia, only that there was an association between using the drugs and a higher risk of developing dementia.
Scientists don’t yet know what causes long COVID, the catch-all term for about 200 widely varying symptoms.
A large study showed that older adults with a higher risk of dementia may be able to reduce their risk of cognitive decline by almost 50 percent by using hearing aids.
If U.S. regulators approve, the drug would be only the second Alzheimer’s treatment convincingly shown to delay the mind-robbing disease—after rival Leqembi. Both drugs pose a serious safety concern—brain swelling and bleeding.
The National Institutes of Health awarded the grant to the Indiana Clinical and Translational Sciences Institute, a partnership among Indiana University, Purdue University and University of Notre Dame.
Fred Cate, IU’s vice president for research, informed federal officials that the research group had “a pattern of non-compliance” and had been warned several times against using expired materials.
Five of the top 10 research studies that received the most NIH funding at the medical school were for Alzheimer’s disease or brain aging, one of the school’s top priorities.
Dr. Rachel Patzer, director of the Health Services Research Center at the Emory University School of Medicine in Atlanta, will join Regenstrief Institute on May 1.
Researchers at Indiana University School of Medicine are hoping to gain new insights into the defect, called coarctation of the aorta, or narrowing of the aorta that obstructs blood flow to vital organs.
The high-tech approach allows a patient recovering from substance abuse to interact with potential future versions of himself or herself.
After 15 years of coaxing and cajoling the medical community to consider a different way to do brain surgery, NICO co-founder Jim Pearson has numbers to show more surgeons and investors are buying into his vision.
Here’s how beagles being bred for research by an Indianapolis-based company became the target of the largest animal welfare seizure in the Humane Society’s history.
The money will be used to study animal models of late-onset Alzheimer’s disease as well as perform rigorous testing of potential therapeutics in animals.